Healthcare Facilities company Aster DM Healthcare announced Q2FY26 results Revenue for Q2FY26 grew 10% YoY and 11% QoQ to Rs 1,197 crore. Operating EBITDA grew 13% YoY and 22% QoQ to Rs 263 crore. in Q2FY26. Operating EBITDA Margins stood at 22.0% in Q2FY26 vs 21.4% in Q2FY25 and 20.0% in Q1FY26. Normalised PAT (Post NCI) grew 14% YoY and 23% QoQ to Rs 110 crore. In Q2FY26. Azad Moopen, Founder & Chairman, Aster DM Healthcare, said: “Aster DM Healthcare delivered a steady performance in Q2FY26, with revenue increasing 10% yearon-year to Rs 1,197 crore despite lower incidence of seasonal illness. Adjusting for thistemporary seasonal effect, the company’s underlying revenue growth stood at 13%, demonstrating the strength of its core business operations. Operating EBITDA grew by 13% YoY and 22% QoQ during the quarter, reflecting stronger cost efficiency and operating leverage across the network. The Kerala cluster demonstrated a strong turnaround in FY26, emerging from last year’s softness with renewed momentum and discipline. Following decisive leadership strengthening, operational tightening, and the revival of MVT partnerships, performance rebounded sharply. In Q2FY26, Kerala delivered its highest-ever quarterly revenue of Rs 620 crore with QoQ growth of 12%, driven by inpatient volumes growing by 13% QoQ and MVT revenue surging 67% QoQ. This momentum will further be supported with the recently operationalized 264-bedded Aster Kasaragod, strengthening our presence in northern Kerala. We have made progress on the merger with Quality Care India Ltd. with stock exchange no-objection letters now received. The combined platform will create one of India’s most integrated and scalable healthcare networks, with complementary cluster strengths and enhanced clinical depth. Together with ongoing investments in digital health and efficiency-focused operating improvements, Aster remains well-positioned to deliver sustainable, long-term growth across its key markets.” Result PDF
Capital Markets company Multi Commodity Exchange of India announced Q2FY26 results Revenue from Operations Rs 374.23 crore, registering a growth of ~ 31% over Q2FY25. EBITDA increased to Rs 270.19 crore, ~32% YoY growth. Profit After Tax (PAT) Rs 197.47 crore, ~29% YoY growth. Average Daily Turnover (ADT) increased to Rs 411,270 crore, reflecting the trust of our stakeholders and market participants alike. Praveena Rai, Managing Director & CEO, MCX, said: “It gives me great pleasure to share our results of resilient performance. Our continued growth across product segments and strong participation reflect the confidence that market participants have in MCX’s transparent market ecosystem. We remain committed to expanding our product offerings and deepening market penetration, further strengthening our role as the preferred destination for commodity derivatives trading in India. MCX continues to strengthen its leadership in India’s commodity derivatives market by enhancing technology infrastructure, deepening market participation, and introducing innovative products that cater to the evolving needs of stakeholders”. Result PDF